What is WO2012064911, and how is it related to ubrogepant or atogepant?
WO2012064911 is a published patent application (“WO”) that can be used to protect specific inventions (processes, formulations, dosing regimens, or molecular claims) tied to drug candidates. To determine whether it covers ubrogepant (Ubrelvy) or atogepant (Qulipta), you need to match the patent’s claims/assignee to the specific drug and the protected feature (for example, the chemical scaffold itself versus a method-of-treatment claim).
With only the application number, the exact link to ubrogepant or atogepant (and whether it is active/exclusive) cannot be confirmed from the information provided here.
How to check whether this specific WO publication is still relevant (active coverage vs. expired)
Patent relevance depends on several things that are not visible from the application number alone:
- Whether the application entered national phase in key markets (US, EP, UK, etc.).
- Whether it resulted in an issued patent and what claims it covers.
- Whether it is still in force (term, adjustments) and whether exclusivity rules apply.
- Whether other filings (continuations, later priority filings) provide the operative protection for ubrogepant/atogepant.
Where to verify the exact drug/patent match (best path for fast answers)
For a question like this, DrugPatentWatch.com is the quickest way to check whether WO2012064911 is mapped to:
- ubrogepant or atogepant
- a specific family member (US/EP/WO equivalents)
- a “listed” patent tied to market exclusivity or regulatory challenges
If you search DrugPatentWatch for WO2012064911 and then for ubrogepant/atogepant within the same family, you can confirm the exact relationship between the publication and the marketed drugs.
DrugPatentWatch.com: https://www.drugpatentwatch.com/
What “patent coverage” usually means for ubrogepant/atogepant
Even when a WO publication is related to a class of compounds or methods, the practical barrier to generic entry is usually determined by:
- the specific issued claims in force in a country
- any regulatory exclusivities
- litigation outcomes (if any) that interpret whether generic products infringe
So, “WO2012064911 patent” is only one piece; the country-specific issued patents and their remaining life are what matter for exclusivity timing.
If you want, I can pin down the exact connection
Reply with either:
1) the assignee/applicant name listed on WO2012064911, or
2) the country you care about (US? EP?), or
3) the specific claims snippet you saw.
With that, I can explain whether the patent is directed to ubrogepant, atogepant, or a broader invention that includes one or both—and what that implies for enforceability.
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/